Evolus (EOLS) Competitors

Phibro Animal Health has higher revenue and earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Evolus presently has a consensus target price of $14.50, suggesting a potential upside of 91.55%. Phibro Animal Health has a consensus target price of $42.50, suggesting a potential upside of 24.45%. Given Evolus' stronger consensus rating and higher probable upside, equities analysts plainly believe Evolus is more favorable than Phibro Animal Health.

In the previous week, Evolus had 13 more articles in the media than Phibro Animal Health. MarketBeat recorded 14 mentions for Evolus and 1 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 1.18 beat Evolus' score of 0.32 indicating that Phibro Animal Health is being referred to more favorably in the news media.

Phibro Animal Health has a net margin of 6.35% compared to Evolus' net margin of -10.85%. Phibro Animal Health's return on equity of 37.14% beat Evolus' return on equity.

90.7% of Evolus shares are held by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are held by institutional investors. 5.0% of Evolus shares are held by company insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Evolus has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market. Comparatively, Phibro Animal Health has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market.

Evolus has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market. Comparatively, Harrow has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

Evolus currently has a consensus price target of $14.50, indicating a potential upside of 91.55%. Harrow has a consensus price target of $69.43, indicating a potential upside of 70.59%. Given Evolus' higher probable upside, research analysts plainly believe Evolus is more favorable than Harrow.

In the previous week, Evolus had 6 more articles in the media than Harrow. MarketBeat recorded 14 mentions for Evolus and 8 mentions for Harrow. Harrow's average media sentiment score of 0.59 beat Evolus' score of 0.32 indicating that Harrow is being referred to more favorably in the news media.

Harrow has lower revenue, but higher earnings than Evolus. Harrow is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks.

90.7% of Evolus shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 5.0% of Evolus shares are owned by insiders. Comparatively, 12.8% of Harrow shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Harrow has a net margin of -5.57% compared to Evolus' net margin of -10.85%. Harrow's return on equity of 19.59% beat Evolus' return on equity.

In the previous week, Perrigo had 3 more articles in the media than Evolus. MarketBeat recorded 17 mentions for Perrigo and 14 mentions for Evolus. Perrigo's average media sentiment score of 0.74 beat Evolus' score of 0.32 indicating that Perrigo is being referred to more favorably in the media.

Evolus has a net margin of -10.85% compared to Perrigo's net margin of -41.85%. Perrigo's return on equity of 11.25% beat Evolus' return on equity.

Perrigo currently has a consensus target price of $19.33, suggesting a potential upside of 52.35%. Evolus has a consensus target price of $14.50, suggesting a potential upside of 91.55%. Given Evolus' stronger consensus rating and higher probable upside, analysts clearly believe Evolus is more favorable than Perrigo.

Evolus has lower revenue, but higher earnings than Perrigo. Evolus is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Perrigo has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, Evolus has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market.

95.9% of Perrigo shares are owned by institutional investors. Comparatively, 90.7% of Evolus shares are owned by institutional investors. 0.4% of Perrigo shares are owned by insiders. Comparatively, 5.0% of Evolus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

90.7% of Evolus shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 5.0% of Evolus shares are owned by insiders. Comparatively, 4.4% of Xeris Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Evolus has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

In the previous week, Xeris Biopharma had 10 more articles in the media than Evolus. MarketBeat recorded 24 mentions for Xeris Biopharma and 14 mentions for Evolus. Evolus' average media sentiment score of 0.32 beat Xeris Biopharma's score of -0.07 indicating that Evolus is being referred to more favorably in the media.

Evolus presently has a consensus target price of $14.50, indicating a potential upside of 91.55%. Xeris Biopharma has a consensus target price of $10.80, indicating a potential upside of 35.17%. Given Evolus' higher probable upside, analysts plainly believe Evolus is more favorable than Xeris Biopharma.

Xeris Biopharma has lower revenue, but higher earnings than Evolus. Xeris Biopharma is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks.

Xeris Biopharma has a net margin of -5.12% compared to Evolus' net margin of -10.85%. Xeris Biopharma's return on equity of 158.10% beat Evolus' return on equity.